Argonaut Therapeutics is assembling an international team of scientists and clinicians that strive to combat cancer through developing innovative and proprietary therapies. Argonaut Therapeutics has pioneered the development of inhibitors of protein arginine methyl-transferase (PRMT).
Arginine methylation is established to be an important type of protein modification. Historically, it was first described to influence gene expression, at different levels of control for example chromatin, RNA processing and splicing, and transcription. Today, it is regarded much more as a general modification which exerts control over diverse proteins and pathways. In human cells, the methylation event is catalysed by a family of protein arginine methyl transferases (PRMTs) with nine members; the type I PRMT enzymes catalyse asymmetric (asymR) methylation and include PRMT1, and the type II symmetric (symR) methylation and include PRMT5.
Argonaut’s most advanced product is a small molecule drug which inhibits PRMT5 and activates pathways which lead to cancer cell death. A companion diagnostic enables a precision medicine approach to treating patients. Argonaut has a number of preclinical programmes underway.